Targeting two‐pore domain K+channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Depression is a disease that is particularly frequent, affecting up to 20% of the population in W estern countries. The origins of this pathology involve multiple genes as well as environmental and developmental factors leading to a disorder that remains difficult to treat. Several therapies for depression have been developed and these mainly target monoamine neurotransmitters. However, these treatments are not only associated with numerous adverse effects, but they are also ineffective for more than one‐third of patients. Therefore, the need to develop new concepts to treat depression is crucial. Recently, studies using knockout mouse models have provided evidence for a crucial role of two members of the two‐pore domain potassium channel (K 2P) family, tandem P‐domain weak inward rectifying K+(TWIK)‐related K+channel 1 (TREK‐1) and TWIK‐related acid‐sensitive K+channel 3 (TASK‐3) in the pathophysiology of depression. It is believed that TREK‐1 and TASK‐3 antagonists could lead to the development of new antidepressants. Herein, we describe the discovery of spadin, a natural peptide released from the maturation of the neurotensin receptor‐3 (also known as sortilin), which specifically blocks the activity of the TREK‐1 channel and displays particular antidepressant properties, with a rapid onset of action and the absence of adverse effects. The development of such molecules may open a new era in the field of psychiatry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 2×
“…to several inducible depression-like states (Heurteaux et al., 2006), as revealed by the use of current behavioural tests (Table 1) (Porsolt et al., 1977; Kameyama et al., 1985; Caldarone et al., 2000; Porsolt, 2000; Cryan et al., 2002; Santarelli et al., 2003; Cryan and Mombereau, 2004).”
BackgroundNibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962 · cited 1×
“At the cellular level, sortilin binds neurotensin, the precursor of the nerve growth factor, the receptorassociated protein and the lipoprotein lipase (Petersen et al., 1997; Mazella et al., 1998; Nielsen et al., 1999; Nykjaer et al., 2004).”
BackgroundResearch and treatment approaches to depression
Wong, M.-L., & Licinio, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072566 · Cited by 656 · cited 1×
“All current ADs also have a slow onset of action, which may take several weeks to months to produce a therapeutic response and are only moderately effective, leaving more than one-third of depressed individuals resistant to drug treatments (Wong and Licinio, 2001).”
BackgroundInhalational anesthetics activate two-pore-domain background K+ channels
Patel, A. J., Honoré, E., Lesage, F., Fink, M., Romey, G., & Lazdunski, M. (1999) · Nature Neuroscience · doi:10.1038/8084 · Cited by 655 · cited 2×
“TREK-1 and TREK-2 are opened by clinical concentrations of volatile anaesthetics (Patel et al., 1999) and by riluzole, a neuroprotective drug used in amyotrophic lateral sclerosis (Duprat et al., 2000).”
BackgroundCryan, J. F., & Mombereau, C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001457 · Cited by 616 · cited 2×
“…to several inducible depression-like states (Heurteaux et al., 2006), as revealed by the use of current behavioural tests (Table 1) (Porsolt et al., 1977; Kameyama et al., 1985; Caldarone et al., 2000; Porsolt, 2000; Cryan et al., 2002; Santarelli et al., 2003; Cryan and Mombereau, 2004).”
BackgroundCNS Distribution of Members of the Two-Pore-Domain (KCNK) Potassium Channel Family
Talley, E. M., Solórzano, G., Lei, Q., Kim, D., & Bayliss, D. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07491.2001 · Cited by 573
TREK-1, a K+ channel involved in neuroprotection and general anesthesia
Heurteaux, C., Guy, N., Laigle, C., Blondeau, N., Duprat, F., Mazzuca, M., Lang‐Lazdunski, L., Widmann, C., Zanzouri, M., Romey, G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600234 · Cited by 534
Self-citationJiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527 · cited 1×
“A number of studies have shown that these cannabinoid agonists and indirect agonists (inhibitors of degradation of endocannabinoid ligands anadamide and 2-arachidonoylglycerol) produce AD-like effects in mouse models (Gobbi et al., 2005; Jiang et al., 2005; Zhong et al., 2014).”
BackgroundPang, D. S. J., Robledo, C. J., Carr, D. R., Gent, T. C., Vyssotski, A. L., Caley, A., Zecharia, A. Y., Wisden, W., Brickley, S. G., & Franks, N. P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907228106 · Cited by 97 · cited 2×
“Continuous EEG/EMG recordings reveal that TASK-3 KO mice exhibit a slower progression from their waking to sleeping states and, during their sleeping period, their sleep episodes as well as their rapid eye movement (REM) θ oscillations are more fragmented (Pang et al., 2009; Gotter et al., 2011).”
BackgroundDeng, P.-Y., & Lei, S. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.005 · Cited by 71
Cited by
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212
Donegan, M. L., Stefanini, F., Meira, T., Gordon, J. A., Fusi, S., & Siegelbaum, S. A. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00720-5 · Cited by 114
Li, L., Sun, H., Ding, J., Niu, C., Su, M., Zhang, L., Li, Y., Wang, C., Gamper, N., Du, X., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14026 · Cited by 51
“One emerging concept for treating depression is focused on modulation of the K+ channels of VTA dopaminergic neurons (Overstreet and Wegener, 2013; Borsotto et al., 2015).”
BackgroundBortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Türkaydin, B., Schewe, M., Riel, E. B., Schulz, F., Biedermann, J., Baukrowitz, T., & Sun, H. (2024) · Nature Communications · doi:10.1038/s41467-024-48823-y · Cited by 23
Metadata
- Authors
- Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-11-24
- Volume
- 172
- Issue
- 3
- Pages
- 771-784
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2123932081
- Cited by
- 63
- References
- 12
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.